ライフサイエンスコーパス: castration-resistant prostate cancer

1 esistant prostate cancer) and LDP4 (12 of 21 castration-resistant prostate cancer).

2 in men with chemotherapy-naive, metastatic, castration-resistant prostate cancer.

3 to licensing for the treatment of metastatic castration-resistant prostate cancer.

4 nt further studies of 6 for the treatment of castration-resistant prostate cancer.

5 ion that provided new insights in metastatic castration-resistant prostate cancer.

6 d not improve OS in patients with metastatic castration-resistant prostate cancer.

7 symptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.

8 tandard of care for patients with metastatic castration-resistant prostate cancer.

9 e therapy response and prognosis in men with castration-resistant prostate cancer.

10 ith bicalutamide in patients with metastatic castration-resistant prostate cancer.

11 only agent with proven survival benefit for castration-resistant prostate cancer.

12 undergoing further development in metastatic castration-resistant prostate cancer.

13 chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

14 nt in chemotherapy-naive men with metastatic castration-resistant prostate cancer.

15 tivity is the main driver for development of castration-resistant prostate cancer.

16 e treatment of androgen-sensitive as well as castration-resistant prostate cancer.

17 onal activity and promote the development of castration-resistant prostate cancer.

18 validated therapeutic target for metastatic castration-resistant prostate cancer.

19 o improvement in the treatment of metastatic castration-resistant prostate cancer.

20 patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

21 chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

22 tamide, a drug approved for the treatment of castration-resistant prostate cancer.

23 for chemotherapy-naive men with metastatic, castration-resistant prostate cancer.

24 navir or its analogs should be developed for castration-resistant prostate cancer.

25 chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

26 AR output signature, is low in a portion of castration-resistant prostate cancer.

27 the androgen receptor and the development of castration-resistant prostate cancer.

28 clinical responses with ODM-201 in men with castration-resistant prostate cancer.

29 able to inhibit AR transactivation and treat castration-resistant prostate cancer.

30 sing direct STAT3 inhibitor for treatment of castration-resistant prostate cancer.

31 irst-line docetaxel treatment for metastatic castration-resistant prostate cancer.

32 skeletal events in patients with metastatic castration-resistant prostate cancer.

33 inetics, and activity in men with metastatic castration-resistant prostate cancer.

34 the RLT and care of patients with metastatic castration-resistant prostate cancer.

35 yday functioning of patients with metastatic castration-resistant prostate cancer.

36 is a retrospective study of 38 patients with castration-resistant prostate cancer.

37 ase III clinical trials for the treatment of castration-resistant prostate cancer.

38 of chemotherapy in patients with metastatic castration-resistant prostate cancer.

39 mide was recently approved for patients with castration-resistant prostate cancer.

40 chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

41 l for chemotherapy-naive men with metastatic castration-resistant prostate cancer.

42 P/p300 is required to maintain the growth of castration-resistant prostate cancer.

43 el, a first-line chemotherapy for metastatic castration-resistant prostate cancer.

44 alidomide, are also in active development in castration-resistant prostate cancer.

45 f bone metastasis or death in non-metastatic castration-resistant prostate cancer.

46 II study that enrolled 34 men with advanced castration-resistant prostate cancer.

47 ipt-based model as a prognostic biomarker in castration-resistant prostate cancer.

48 ith mitoxantrone in patients with metastatic castration-resistant prostate cancer.

49 1 (14 of 14) and most in LPD2 (17 of 18) had castration-resistant prostate cancer.

50 overall survival in patients with metastatic castration-resistant prostate cancer.

51 erapeutic option in patients with metastatic castration-resistant prostate cancer.

52 rials that enrolled patients with metastatic castration-resistant prostate cancer.

53 6 signaling as a central mechanism mediating castration-resistant prostate cancer.

54 rivation therapy and in approximately 30% of castration-resistant prostate cancer.

55 CBP/p300 bromodomain as a strategy to treat castration-resistant prostate cancer.

56 ion that provided new insights in metastatic castration-resistant prostate cancer.

57 3 is a potential target for the treatment of castration-resistant prostate cancer.

58 and is approved for patients with metastatic castration-resistant prostate cancer.

59 1, 2009, and July 31, 2013, with metastatic castration-resistant prostate cancer.

60 etastasis is the hallmark of progressive and castration-resistant prostate cancers.

61 benefit as a novel alternative treatment for castration-resistant prostate cancers.

62 is a mediator of both androgen-dependent and castration-resistant prostate cancers.

63 llows functional substitution for AR in some castration-resistant prostate cancers.

64 overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy.

65 rolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy.

66 plus prednisone in patients with metastatic castration-resistant prostate cancer after docetaxel che

67 the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression w

68 esponses in asymptomatic men with metastatic castration-resistant prostate cancer and also resensitis

69 r skeletal-related events (SREs) in men with castration-resistant prostate cancer and bone metastases

70 m-223 compared with placebo in patients with castration-resistant prostate cancer and bone metastases

71 improve overall survival or PFS in men with castration-resistant prostate cancer and bone metastases

72 on to the best standard of care, in men with castration-resistant prostate cancer and bone metastases

73 le for participation if they had: metastatic castration-resistant prostate cancer and had received no

74 ely active in several malignancies including castration-resistant prostate cancer and has been identi

75 ional program in both androgen-sensitive and castration-resistant prostate cancer and inhibited tumou

76 rs are available to predict the emergence of castration-resistant prostate cancer and no curative opt

77 cruited patients with progressive metastatic castration-resistant prostate cancer and no previous che

78 lected into PAXgene tubes from patients with castration-resistant prostate cancer and patients with p

79 ing continued androgen receptor signaling in castration-resistant prostate cancer and provides an ove

80 ffective and well tolerated in patients with castration-resistant prostate cancer and symptomatic bon

81 cebo and was well tolerated in patients with castration-resistant prostate cancer and symptomatic bon

82 ered as a treatment option for patients with castration-resistant prostate cancer and symptomatic bon

83 sly reported ALSYMPCA trial in patients with castration-resistant prostate cancer and symptomatic bon

84 en receptor-regulated miRNA overexpressed in castration-resistant prostate cancer and that miR-32 can

85 role for BAT in the management of metastatic castration-resistant prostate cancer and the optimal str

86 Patients with castration-resistant prostate cancer and those under act

87 validate the activation function of EZH2 in castration-resistant prostate cancer and to (ii) study t

88 It occurred in both androgen-dependent and castration-resistant prostate cancer and was associated

89 active surveillance comprised LPD3 (15 of 31 castration-resistant prostate cancer) and LDP4 (12 of 21

90 r older with chemotherapy-naive, metastatic, castration-resistant prostate cancer, and adequate organ

91 newly diagnosed prostate cancer but also in castration-resistant prostate cancer, and our understand

92 in human NEPC tumors compared to primary and castration-resistant prostate cancers, and its expressio

93 ditional cohorts (post-abiraterone and newly castration-resistant prostate cancer) are ongoing.

94 bo-controlled study, men with non-metastatic castration-resistant prostate cancer at high risk of bon

95 us prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim anal

96 nd ALSYMPCA trial, patients with symptomatic castration-resistant prostate cancer, at least two sympt

97 (1245A>C) has been mechanistically linked to castration-resistant prostate cancer because it encodes

98 a-118b, a patient-derived xenograft (PDX) of castration-resistant prostate cancer bone metastasis tha

99 tion of survival in patients with metastatic castration-resistant prostate cancer but also engage a c

100 drogen synthesis and treat lethal metastatic castration-resistant prostate cancer, but drug developme

101 xpression of miR-23b/-27b in two independent castration-resistant prostate cancer cell lines resulted

102 introduction of miR-23b/-27b in metastatic, castration-resistant prostate cancer cell lines resulted

103 short hairpin RNA targeting these lncRNAs in castration-resistant prostate cancer cell lines strongly

104 In examining androgen-responsive and castration-resistant prostate cancer cells and primary t

105 ive and an androgen-independent mechanism in castration-resistant prostate cancer cells.

106 the proliferation of androgen-dependent and castration-resistant prostate cancer cells.

107 ble targets that reduce the proliferation of castration-resistant prostate cancer cells.

108 occur early are an unmet need in metastatic castration-resistant prostate cancer clinical research a

109 sponse end points for early-phase metastatic castration-resistant prostate cancer clinical trials.

110 chemotherapy-naive patients with metastatic castration-resistant prostate cancer compared with predn

111 tive prostate cancer typically progresses to castration resistant prostate cancer (CRPC) after the an

112 axis regulates multiple oncogenic drivers of castration resistant prostate cancer (CRPC).

113 5alpha-dihydrotestosterone, respectively, in castration resistant prostate cancer (CRPC).

114 st bone metastasis in men with nonmetastatic castration-resistant prostate cancer (CRPC) and baseline

115 , there are still no curative treatments for castration-resistant prostate cancer (CRPC) and, therefo

116 The precise molecular alterations driving castration-resistant prostate cancer (CRPC) are not clea

117 or, improves survival in men with metastatic castration-resistant prostate cancer (CRPC) before and a

118 ndrogen-dependent prostate cancer (ADPC) and castration-resistant prostate cancer (CRPC) cell lines,

119 rapies have significantly improved survival, castration-resistant prostate cancer (CRPC) cells are ev

120 the growth of androgen-dependent as well as castration-resistant prostate cancer (CRPC) cells in vit

121 Finally, androgen-independent AR activity in castration-resistant prostate cancer (CRPC) cells is dri

122 environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical tri

123 Castration-resistant prostate cancer (CRPC) continues to

124 Castration-resistant prostate cancer (CRPC) continues to

125 sed in advanced prostate cancer, its role in castration-resistant prostate cancer (CRPC) driven by PT

126 The current standard for imaging castration-resistant prostate cancer (CRPC) focuses sole

127 Patients with metastatic castration-resistant prostate cancer (CRPC) frequently d

128 recently discovered mechanisms that sustain castration-resistant prostate cancer (CRPC) growth and d

129 The view of castration-resistant prostate cancer (CRPC) has changed

130 he activity of cabozantinib in patients with castration-resistant prostate cancer (CRPC) in a phase I

131 Men who develop metastatic castration-resistant prostate cancer (CRPC) invariably s

132 Progression of primary prostate cancer to castration-resistant prostate cancer (CRPC) is associate

133 The development of castration-resistant prostate cancer (CRPC) is associate

134 Castration-resistant prostate cancer (CRPC) is character

135 The lethal phenotype of castration-resistant prostate cancer (CRPC) is generally

136 Castration-resistant prostate cancer (CRPC) is the letha

137 Castration-resistant prostate cancer (CRPC) is the main

138 Metastatic castration-resistant prostate cancer (CRPC) is the prima

139 Trials in castration-resistant prostate cancer (CRPC) need new cli

140 nce of prostate cancer either in the form of castration-resistant prostate cancer (CRPC) or transdiff

141 used clinical tissue from lethal metastatic castration-resistant prostate cancer (CRPC) patients obt

142 Castration-resistant prostate cancer (CRPC) remains a ma

143 ntinues to have a critical role in promoting castration-resistant prostate cancer (CRPC) survival and

144 the progression of prostate cancer (PCa) and castration-resistant prostate cancer (CRPC) through upre

145 rk [ACRIN] 6687) to a multicenter metastatic castration-resistant prostate cancer (CRPC) tissue bioma

146 ough initially effective, leads to incurable castration-resistant prostate cancer (CRPC) via compensa

147 circulating tumor cells (CTCs) from men with castration-resistant prostate cancer (CRPC) was associat

148 onal therapy for chemotherapy-naive men with castration-resistant prostate cancer (CRPC) who range fr

149 n-dependent and in castration-resistant CaP (castration-resistant prostate cancer (CRPC)) cell lines.

150 s the first therapeutic approach in treating castration-resistant prostate cancer (CRPC), but tumours

151 efficacy and promotes progression to lethal castration-resistant prostate cancer (CRPC), even when p

152 ing tumors, most patients eventually develop castration-resistant prostate cancer (CRPC), for which t

153 (AR), a central player in the development of castration-resistant prostate cancer (CRPC), holds promi

154 (LBD) are associated with the development of castration-resistant prostate cancer (CRPC), including r

155 roved for the treatment of docetaxel-treated castration-resistant prostate cancer (CRPC), is often ef

156 articularly virulent form of this disease is castration-resistant prostate cancer (CRPC), where patie

157 o remission, the disease often progresses to castration-resistant prostate cancer (CRPC), which is st

158 evelopment of novel treatment strategies for castration-resistant prostate cancer (CRPC).

159 potential therapeutic target for metastatic castration-resistant prostate cancer (CRPC).

160 inevitably relapses and progresses to lethal castration-resistant prostate cancer (CRPC).

161 of the predominantly upregulated pathways in castration-resistant prostate cancer (CRPC).

162 receptor (AR) activity are major drivers of castration-resistant prostate cancer (CRPC).

163 patients will relapse and develop incurable castration-resistant prostate cancer (CRPC).

164 biraterone and enzalutamide in patients with castration-resistant prostate cancer (CRPC).

165 a phase II nonrandomized expansion study in castration-resistant prostate cancer (CRPC).

166 approval of abiraterone for the treatment of castration-resistant prostate cancer (CRPC).

167 nts applied to (18)F-fluorocholine PET/CT in castration-resistant prostate cancer (CRPC).

168 (ADT) and their subsequent development into castration-resistant prostate cancer (CRPC).

169 apies used to treat patients with metastatic castration-resistant prostate cancer (CRPC).

170 However, tumors often recur, forming castration-resistant prostate cancer (CRPC).

171 eceptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC).

172 n with docetaxel in patients with metastatic castration-resistant prostate cancer (CRPC).

173 ly fail and the disease progresses to lethal castration-resistant prostate cancer (CRPC).

174 cer cells to survive, adapt, and evolve into castration-resistant prostate cancer (CRPC).

175 R-targeted therapy and progression to lethal castration-resistant prostate cancer (CRPC).

176 her with Pten, leading to the development of castration-resistant prostate cancer (CRPC).

177 and this recurrent cancer is referred to as castration-resistant prostate cancer (CRPC).

178 opment and progression to lethal, metastatic castration-resistant prostate cancer (CRPC).

179 genic pathways that contribute to metastatic castration-resistant prostate cancer (CRPC).

180 s receiving ADT eventually develop incurable castration-resistant prostate cancer (CRPC).

181 cancer deaths due to disease progression to castration-resistant prostate cancer (CRPC).

182 rapy failure leads to terminal and incurable castration-resistant prostate cancer (CRPC).

183 and PPP3CC is formed during the emergence of castration-resistant prostate cancer (CRPC).

184 is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC).

185 o detect metastatic hormone-naive (HNPC) and castration-resistant prostate cancer (CRPC).

186 Taxanes are a standard of care therapy in castration-resistant prostate cancer (CRPC); however, me

187 Castration-resistant prostate cancers (CRPC) that arise

188 Proteomic analysis of castration-resistant prostate cancer demonstrated the en

189 y androgen biosynthetic enzyme implicated in castration-resistant prostate cancer development.

190 still be very effective in the treatment of castration-resistant prostate cancer, even after the use

191 report that approximately 20% of metastatic castration-resistant prostate cancers express neither AR

192 ion of FOXA1 in inhibiting AR signalling and castration-resistant prostate cancer growth.

193 progressing on androgen-deprivation therapy (castration-resistant prostate cancer) has improved subst

194 Patients with metastatic castration-resistant prostate cancer have few treatment

195 rovements to prognostic models in metastatic castration-resistant prostate cancer have the potential

196 y-naive patients with progressive metastatic castration-resistant prostate cancer in a 1:1 ratio to r

197 ting tumor cells in patients with metastatic castration-resistant prostate cancer in a phase I clinic

198 6, to June, 2008, and from 140 patients with castration-resistant prostate cancer in a validation set

199 hat prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease

200 oma xenografts to androgen withdrawal led to castration-resistant prostate cancer, including the firs

201 Survival for patients with castration-resistant prostate cancer is highly variable.

202 th metastatic breast and six with metastatic castration-resistant prostate cancer, isolated via CellS

203 el in chemotherapy-naive men with metastatic castration-resistant prostate cancer led to greater effi

204 n circulating tumor cells from patients with castration-resistant prostate cancer may be associated w

205 Elevated androgen receptor (AR) activity in castration-resistant prostate cancer may occur through i

206 docetaxel cycles in patients with metastatic castration resistant prostate cancer (mCPRC) has not bee

207 ressed in sera from patients with metastatic castration resistant prostate cancer (mCRPC) as compared

208 widely used drug in patients with metastatic castration resistant prostate cancer (mCRPC).

209 ll survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after docet

210 I]) in patients who have advanced metastatic castration-resistant prostate cancer (mCRPC) and are rec

211 l-related events in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone me

212 established prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) and the ass

213 o androgen receptor inhibition in metastatic castration-resistant prostate cancer (mCRPC) and whether

214 l survival (OS) for patients with metastatic castration-resistant prostate cancer (mCRPC) are dated a

215 clear medicine is theranostics of metastatic castration-resistant prostate cancer (mCRPC) based on mo

216 ist enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) is undefine

217 cal decision in the management of metastatic castration-resistant prostate cancer (mCRPC) is when to

218 tumor cells (CTC) from 179 unique metastatic castration-resistant prostate cancer (mCRPC) patients to

219 Whole-exome sequencing of metastatic castration-resistant prostate cancer (mCRPC) reveals tha

220 rogression-free survival (PFS) in metastatic castration-resistant prostate cancer (mCRPC) trials has

221 d Methods Fifty-six patients with metastatic castration-resistant prostate cancer (mCRPC) with osseou

222 For chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC), abirateron

223 r vaccines have shown activity in metastatic castration-resistant prostate cancer (mCRPC), and method

224 Purpose In patients with metastatic castration-resistant prostate cancer (mCRPC), overall su

225 precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we establi

226 -mesenchymal transition (EMT) and metastatic castration-resistant prostate cancer (mCRPC), which is c

227 ) ((177)Lu-PSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC).

228 g resistance mechanism to anti-AR therapy in castration-resistant prostate cancer (mCRPC).

229 f care for frontline treatment of metastatic castration-resistant prostate cancer (mCRPC).

230 ses to treatment in patients with metastatic castration-resistant prostate cancer (mCRPC).

231 randomized, double-blind trial of metastatic castration-resistant prostate cancer (mCRPC).

232 overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).

233 lly significant co-occurrences in metastatic castration-resistant prostate cancer (mCRPC).

234 relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC).

235 nd therapy (RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC).

236 s), and subsequent progression to metastatic castration-resistant prostate cancer (mCRPC).

237 get for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC).

238 ty in men with previously treated metastatic castration-resistant prostate cancer (mCRPC).

239 rolled phase II trial in men with metastatic castration-resistant prostate cancer (mCRPC).

240 n a large cohort of patients with metastatic castration-resistant prostate cancer (mCRPC).

241 In patients with castration-resistant prostate cancer, numbers of bone le

242 to identify druggable targets in metastatic castration-resistant prostate cancer obtained at rapid a

243 was prospectively collected from 62 men with castration-resistant prostate cancer on various treatmen

244 ion of patients for a specific treatment for castration-resistant prostate cancer or the best sequenc

245 PET/CT in the prediction of survival in both castration-resistant prostate cancer patients and hormon

246 on of kinase activation states in metastatic castration-resistant prostate cancer patients have allow

247 e PET/CT as a diagnostic tool for monitoring castration-resistant prostate cancer patients treated wi

248 Thirty-five castration-resistant prostate cancer patients with multi

249 iation therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with prost

250 te cancer cell lines and cfDNA obtained from castration-resistant prostate cancer patients.

251 athway under androgen-deprived conditions in castration-resistant prostate cancer patients.

252 The processes associated with transition to castration-resistant prostate cancer (PC) growth are not

253 Castration-resistant prostate cancer (PCa) is refractory

254 ly clinical development for the treatment of castration-resistant prostate cancer (PCa).

255 overall survival in patients with metastatic castration-resistant prostate cancer previously treated

256 raterone acetate in patients with metastatic castration-resistant prostate cancer progressing after c

257 prednisone alone in patients with metastatic castration-resistant prostate cancer progressing after c

258 tandard of care for patients with metastatic castration-resistant prostate cancer progressing after d

259 We enrolled patients who had metastatic castration-resistant prostate cancer progressing after t

260 ults show nelfinavir and its analogs inhibit castration-resistant prostate cancer proliferation by bl

261 notherapy in men with progressive metastatic castration-resistant prostate cancer provides disease su

262 chemotherapy-naive patients with metastatic castration-resistant prostate cancer, radiographic progr

263 In stage II (validation-set), patients with castration-resistant prostate cancer recruited from the

264 lliate symptoms and prolong life, metastatic castration-resistant prostate cancer remains incurable.

265 ate homologous recombination (HR) defects in castration-resistant prostate cancers, rendering these t

266 Such castration-resistant prostate cancer represents a major

267 1GSC treatments in mouse xenograft models of castration-resistant prostate cancer resulted in signifi

268 Evaluation of metastatic castration-resistant prostate cancer samples for tyrosin

269 ently approved for the treatment of men with castration-resistant prostate cancer; still, more treatm

270 ble-blind phase 3 trial, men with metastatic castration-resistant prostate cancer, stratified for pro

271 h men with at least one bone metastasis from castration-resistant prostate cancer that had progressed

272 with radiographically documented metastatic castration-resistant prostate cancer that had progressed

273 is approved for the treatment of metastatic castration-resistant prostate cancer that has progressed

274 amined orteronel in patients with metastatic castration-resistant prostate cancer that progressed aft

275 ter radiotherapy in patients with metastatic castration-resistant prostate cancer that progressed aft

276 to evaluate BAT in patients with metastatic castration-resistant prostate cancer that progressed aft

277 urther explored as a treatment of metastatic castration-resistant prostate cancers that have frequent

278 Furthermore, androgen deprivation led to castration-resistant prostate cancers that were composed

279 proteolysis as novel therapeutic targets for castration-resistant prostate cancer therapeutics.

280 nhibit proliferation and induce apoptosis of castration-resistant prostate cancer through inhibition

281 ses are highly expressed in human metastatic castration-resistant prostate cancer tissues.

282 t randomised clinical trials with metastatic castration-resistant prostate cancer to estimate the gro

283 gen and antiandrogen therapies in metastatic castration-resistant prostate cancer to maximise therape

284 ficantly longer for patients with metastatic castration-resistant prostate cancer treated with this c

285 2010, patients with progressive, metastatic castration-resistant prostate cancer were enrolled into

286 e 3 clinical trials in first-line metastatic castration-resistant prostate cancer were obtained from

287 e 2 trial in which patients with metastatic, castration-resistant prostate cancer were treated with o

288 USE M1-in which 266 patients with metastatic castration-resistant prostate cancer were treated with p

289 uctive tract tissues and at higher levels in castration-resistant prostate cancer where it is require

290 hesis and prolongs survival in patients with castration-resistant prostate cancer, which is otherwise

291 aterone acetate for patients with metastatic castration-resistant prostate cancer who progressed afte

292 spectively enrolled patients with metastatic castration-resistant prostate cancer who were initiating

293 Men with progressive metastatic castration-resistant prostate cancer, who had castrate c

294 ssed its effect on survival in patients with castration-resistant prostate cancer with bone metastase

295 d no survival benefit in men with metastatic castration-resistant prostate cancer with the addition o

296 al, we enrolled patients who had symptomatic castration-resistant prostate cancer with two or more bo

297 rmed progressive bone-predominant metastatic castration-resistant prostate cancer with two or more sk

298 We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair de

299 d and radiographically documented metastatic castration-resistant prostate cancer, with no more than

300 patients with chemotherapy-naive metastatic castration-resistant prostate cancer without visceral me